Literature DB >> 21811773

Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin.

Chisako Urata1, Mariko Yoshimura2, Hidekazu Itamura1, Takashi Hisatomi1, Yasushi Kubota1, Noriyasu Fukushima1, Eisaburo Sueoka1, Shinya Kimura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21811773     DOI： 10.1007/s12185-011-0903-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.

Authors:  Can Boga; Hakan Ozdogu; Mahmut Yeral; Ebru Kizilkilic; Lulufer Tamer
Journal:  J Support Oncol       Date:  2007-06

2.  A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

Authors:  J R Brown; J Abramson; E Hochberg; E Mikler; V Dalton; L Werner; H Reynolds; C Thompson; S M McDonough; Y Kuang; J Ritz; D Neuberg; A S Freedman
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

3.  Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.

Authors:  Shinsuke Iida; Takaaki Chou; Shinichiro Okamoto; Hirokazu Nagai; Kiyohiko Hatake; Hirokazu Murakami; Toshiyuki Takagi; Kazuyuki Shimizu; Henry Lau; Kenichi Takeshita; Masaaki Takatoku; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2010-06-18       Impact factor: 2.490

Review 4.  Clinical perspectives of statin-induced rhabdomyolysis.

Authors:  Kenneth A Antons; Craig D Williams; Steven K Baker; Paul S Phillips
Journal:  Am J Med       Date:  2006-05       Impact factor: 4.965

5.  Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.

Authors:  Ellen van der Spek; Andries C Bloem; Henk M Lokhorst; Berris van Kessel; Lijnie Bogers-Boer; Niels W C J van de Donk
Journal:  Leuk Res       Date:  2008-07-14       Impact factor: 3.156

6.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Authors:  Donna M Weber; Christine Chen; Ruben Niesvizky; Michael Wang; Andrew Belch; Edward A Stadtmauer; David Siegel; Ivan Borrello; S Vincent Rajkumar; Asher Alban Chanan-Khan; Sagar Lonial; Zhinuan Yu; John Patin; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

7.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

Review 8.  The safety of statins in clinical practice.

Authors:  Jane Armitage
Journal:  Lancet       Date:  2007-11-24       Impact factor: 79.321
  8 in total
  1 in total

1.  Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.

Authors:  Jaime L Shahan; Lori D Panu; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2012-11-28       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.